GlassScriptPhysician profile
Numan A Khan
NPI 1558756593
$9,711.38
in general payments reported to CMS, 2019-2025
34 companies · $417 in 2025
The $417 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $148 · 2020: $107 · 2021: $3,212 · 2022: $3,313 · 2023: $519 · 2024: $1,995 · 2025: $417.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,042 · Travel and Lodging: $889.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,041.86 |
| Travel and Lodging | $889.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $3,092.75 | 2021-2024 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Medtronic, INC. | $1,557.18 | 2022-2024 | Venaseal |
| Boston Scientific Corporation | $578.34 | 2021-2025 | General - Therapies |
| Shockwave Medical, INC | $393.82 | 2022 | |
| Pfizer INC. | $354.19 | 2019-2022 | |
| Cardiovascular Systems INC. | $348.80 | 2020-2022 | |
| Inari Medical, INC. | $338.55 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $308.86 | 2021-2025 | Eliquis, Camzyos |
| Angiodynamics, INC. | $260.84 | 2022 | |
| Novartis Pharmaceuticals Corporation | $228.39 | 2023-2025 | |
| Amgen INC. | $184.67 | 2021-2025 | Repatha, Repatha |
| Abiomed | $178.45 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $166.04 | 2020-2021 | |
| Novo Nordisk INC | $152.50 | 2022-2024 | Wegovy, Ozempic |
| Bard Peripheral Vascular, INC. | $145.74 | 2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $139.57 | 2021 | |
| Astellas Pharma US INC | $138.64 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $137.53 | 2023 | Lifevest |
| Abbott Laboratories | $127.53 | 2023-2024 | Amplatzer Talisman |
| Scpharmaceuticals INC. | $115.06 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $113.87 | 2022-2023 | |
| Terumo Medical Corporation | $104.35 | 2022 | |
| Saranas, INC. | $88.24 | 2021 | |
| Chiesi USA, INC. | $83.50 | 2022 | |
| Merck Sharp & Dohme LLC | $78.61 | 2022-2024 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.04 | 2022-2023 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $48.64 | 2023 | |
| W. L. Gore & Associates, INC. | $31.81 | 2022 | |
| Amarin Pharma, INC. | $29.80 | 2022-2023 | |
| Cleerly, INC. | $28.78 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Lexicon Pharmaceuticals, INC. | $24.39 | 2024 | |
| Portola Pharmaceuticals, LLC | $21.42 | 2020 | |
| Kiniksa Pharmaceuticals, LTD. | $21.12 | 2023 | Arcalyst |
| Cashflow Solutions, LLC | $14.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Numan Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.